青酸对儿科的不良影响:人口统计学考量
Brooke K Iwamoto1, Ashley M Whitaker1,2, Latanya D Agurs2,3
1Division of Hematology and Oncology, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Journal of child neurology
|July 29, 2025
概括
奇诺巴改善了儿科患者的发作频率,但引起了不良事件. 在青少年女性中更常见的精神病副作用导致更高的停药率.
科学领域:
- 神经学 神经学
- 儿科症 儿科症
- 药理学 药理学是指药理学的学科.
背景情况:
- 耐药性 (DRE) 在儿科患者群体中存在重大挑战.
- 塞诺巴是一种抗发作药物 (ASM),在管理中新兴使用.
- 了解其在儿科DRE中的疗效和安全性是非常重要的.
研究的目的:
- 调查dre.re.患儿儿科患者中赛诺巴马特的疗效和安全性.
- 为了确定与塞诺巴马特使用和不良事件相关的潜在风险因素.
- 探索治疗反应和停止治疗的趋势.
主要方法:
- 对24名患有DRE的儿科患者进行了回顾性分析,这些患者接受了Cenobamate治疗.
- 收集关于发作频率,不良事件 (生理和精神病) 和停药率的数据.
- 统计分析以确定患者特征和结果之间的关联.
主要成果:
- 50%的患者经历了改善的发作频率与cenobamate.
- 超过50%的人报告了生理和/或精神疾病的不良事件.
- 39%的患者因不可容忍的不良事件而停止服用青胺,精神病事件与停止治疗有很强的联系 (75%).
- 精神病学不良事件与女性性别 (100%) 有显著的关联,并表明与青少年年龄的联系.
结论:
- 雪诺巴在儿科DRE中显示出控制的潜力,但存在不良事件的风险.
- 精神病学不良事件,特别是在青少年女性中,是令人担忧的,并强烈预测停药.
- 进一步的研究是有必要的,以阐明风险因素,并优化在儿科中使用cenobamate.
相关概念视频
01:20Antiepileptic Drugs: Potassium Channel Activators
278
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
278
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
451
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
451
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
243
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
243
01:17Antiepileptic Drugs: Calcium Channel Blockers
632
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
632
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
653
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
653
01:14Antiepileptic Drugs: Glutamate Antagonists
517
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
517